We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Innovative Implantable Occluder Treats Isolated ASDs

By HospiMedica International staff writers
Posted on 27 Jul 2021
Print article
Image: The reSept ASD Occluder (Photo courtesy of atHeart Medical)
Image: The reSept ASD Occluder (Photo courtesy of atHeart Medical)
A new atrial septal defect (ASD) occluder aims to establish a new standard of care for structural heart treatments.

The atHeart Medical (Baar, Switzerland) reSept ASD Occluder is a low-profile, metal-free, bioresorbable implant designed to reduce the risk of complications associated with long-term presence of metal in the heart. The occluder is made of bioresorbable filaments connecting two polyester fabric patches, which contain radiopaque markers. Delivered through a 12F sheath and over a standard guidewire, the device is fully deployed with the guidewire in place, providing the opportunity to reattach and reposition when necessary.

After endothelialization, the filaments slowly resorb, with complete resorption demonstrated in-vitro at 24 months. In addition, reSept has been designed to preserve future treatment options requiring surgery; the polyester fabric and the radiopaque markers remain, which may be useful for future transseptal procedure planning. Available in three sizes, the reSept ASD Occluder supports closure of defects of 4-22mm. The device is currently undergoing a prospective global multi-site clinical investigational device exemption (IDE) trial that will enroll up to 250 patients.

“The metal-free frame of the reSept ASD Occluder provides a low-profile that over time is replaced by the patient's tissue, leaving minimal implant behind and restoring a more natural septum when compared to current occluder devices,” said interventional cardiologist Saibal Kar, MD, of Los Robles Regional Medical Center (Thousand Oaks, CA, USA), co-principal investigator of the IDE trial. “This provides a unique opportunity for physicians to effectively address ASDs while being mindful of our patient's potential need for subsequent transseptal procedures.”

An ASD is a congenital defect resulting from an abnormal formation of the septum that divides the upper chamber into a left and right atrium. This can result in blood flow between the two upper heart chambers through the ASD, forming a shunt. As a result, pressure in the lungs may build up, causing less oxygen in the blood. Symptoms can include difficulty breathing, frequent respiratory infections in children, palpitation, and shortness of breath with activity.

Related Links:
atHeart Medical

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Harness System
Neo-Restraint

Print article

Channels

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.